Latest News for: nav1.8

Edit

Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Nav1.8 Inhibitor for the ...

Polk County Itemiser-Observer 04 Mar 2025
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial ....
  • 1
×